Sign inJoin waitlistJoin the waitlist

Matthew Ulrickson

Program Director · University of Arizona College of Medicine - Phoenix

Credentials: · · · · ·

History

University of Arizona College of Medicine - Phoenix
Present
Hematology Section · University of Arizona College of Medicine-Tucson
Present
University of Arizona College of Medicine - Phoenix
Present

Fred Hutchinson Cancer Research Center
2010–2013
University of Washington School of Medicine
Internal Medicine
Massachusetts General Hospital
2007–2010
McGovern Medical School at The University of Texas Health Science Center at Houston
2003–2007

Research

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
New England Journal of Medicine · 2023 · 409 citations
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Nature Medicine · 2022 · 261 citations
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
Blood · 2024 · 139 citations

Olalekan Oluwole
10 papers
Eunice Wang
6 papers
Julio Chavez
6 papers
Caron Jacobsen
5 papers
FL
Frederick Locke
5 papers
Lori Leslie
5 papers
Sattva Neelapu
5 papers
AH
Alex Herrera
4 papers
Amer Beitinjaneh
4 papers
AG
Armin Ghobadi
4 papers
David Rizzieri
4 papers
Hillard Lazarus
4 papers

Clinical trials

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Site PI · Recruiting · Phase 1, Phase 2
A2 Biotherapeutics Inc.
2025–2030
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Site PI · Recruiting · Phase 2
Allogene Therapeutics
2024–2032
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Site PI · Recruiting · Phase 1, Phase 2
A2 Biotherapeutics Inc.
2024–2029
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Site PI · Recruiting
A2 Biotherapeutics Inc.
2021–2029